Benchmark Reaffirms “Buy” Rating for NeoGenomics (NASDAQ:NEO)
NeoGenomics (NASDAQ:NEO – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Benchmark in a research note issued on Tuesday, Benzinga reports. They currently have a $18.00 target price on the medical research company’s stock. Benchmark’s price target points to a potential upside of 20.32% from the company’s previous close. Several other […]
More Stories
Concentric Wealth Management LLC Purchases 148 Shares of Union Pacific Co. (NYSE:UNP)
Concentric Wealth Management LLC grew its position in shares of Union Pacific Co. (NYSE:UNP – Free Report) by 0.8% during...
How Marco Rubio and Mike Waltz Could Shape Trump’s China Policy
By Terri Wu and Lilly Zhou WASHINGTON—Sen. Marco Rubio (R-Fla.) and Rep. Mike Waltz (R-Fla.) are set to have a...
Larson Financial Group LLC Acquires 6,246 Shares of NIKE, Inc. (NYSE:NKE)
Larson Financial Group LLC grew its stake in NIKE, Inc. (NYSE:NKE – Free Report) by 121.7% in the 3rd quarter,...
Prosperity Financial Group Inc. Grows Holdings in Elevance Health, Inc. (NYSE:ELV)
Prosperity Financial Group Inc. increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 13.5% during...
QCR (NASDAQ:QCRH) Reaches New 52-Week High Following Dividend Announcement
QCR Holdings, Inc. (NASDAQ:QCRH – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday...
Mirabella Financial Services LLP Buys 10,632 Shares of Skyworks Solutions, Inc. (NASDAQ:SWKS)
Mirabella Financial Services LLP raised its stake in Skyworks Solutions, Inc. (NASDAQ:SWKS – Free Report) by 210.6% during the third...